News & Upcoming Events
InDevR Ships First Multiplexed COVID-19 Serology Test Kits for Clinical Validation Boulder, CO-9 April 2020– InDevR, Inc., a leader in progressive analytical technologies to support the development and production of ...
Read More
Read More
InDevR Raises $7 million in Series A Financing with Adjuvant Capital Boulder, CO, 10 September 2019 – InDevR, Inc., a biotechnology company focused on developing and commercializing novel analytical technologies ...
Read More
Read More
Clinical validation of the FluChip-8G Influenza A+B Assay for influenza type and subtype identification published in Journal of Clinical Virology Go to Abstract ...
Read More
Read More
Analytical Evaluation of the Microarray-Based FluChip-8G Influenza A+B Assay published in Journal of Virological Methods Go to Abstract ...
Read More
Read More
ASM Microbe 2019 InDevR will be present at the ASM conference in San Francisco in June. Rose Nash will be offering a presentation, "Assessment of the Correlation between Alternative Influenza ...
Read More
Read More
510(k) Market Clearance for FluChip-8G Influenza A+B Assay InDevR receives 510(k) market clearance for the first influenza diagnostic assay capable of distinguishing between seasonal and non-seasonal influenza A subtypes ...
Read More
Read More
